Medicine
Opdualag 240 mg/80 mg per 20 mL injection
Opdualag 240 mg/80 mg per 20 mL injection is a prescription medicine containing Nivolumab and Relatlimab for intravenous use, marketed by ER Squibb & Sons, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store OPDUALAG refrigerated at 2°C to 8°C (36°F to 46°F) in the original…
Key facts
- Active ingredient (INN)
- Nivolumab and Relatlimab
- Brand
- Opdualag
- Strength
- 240 mg/80 mg per 20 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 20 mL
- Marketing authorisation holder
- ER Squibb & Sons
- Manufacturer
- ER Squibb & Sons
- Origin register
- US FDA, United States
- Storage
- Store OPDUALAG refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze or shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FY02 Nivolumab and Relatlimab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 March 2022
- Identifiers
- RxCUI 2596778, 2596784DailyMed set ID b22c9d83-3256-4e17-85f7-f331a504adc6NDC 0003-7125Application BLA761234
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 0003-7125-11 | ER Squibb & Sons | 18 March 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Nivolumab and Relatlimab is a fixed-dose combination of a lymphocyte activation gene-3 blocker and a programmed death receptor-1 blocking antibody indicated for the treatment of adult, among other approved uses. MedsAcross supplies Nivolumab and Relatlimab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Nivolumab and RelatlimabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- OPDUALAG prescribing information (ER Squibb & Sons) · U.S. National Library of Medicine, DailyMed
- Opdualag: European public assessment report (EPAR) · European Medicines Agency
Need Opdualag 240 mg/80 mg per 20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.